Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/66327
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Campo DC Valor Lengua/Idioma
dc.contributor.authorTroca-Marín, José A.-
dc.contributor.authorAlves-Sampaio, Alexandra-
dc.contributor.authorMontesinos, María Luz-
dc.date.accessioned2013-02-07T14:22:52Z-
dc.date.available2013-02-07T14:22:52Z-
dc.date.issued2012-
dc.identifierdoi: 10.1016/j.pneurobio.2012.01.005-
dc.identifierissn: 0301-0082-
dc.identifier.citationProgress in Neurobiology 96(2): 268-282 (2012)-
dc.identifier.urihttp://hdl.handle.net/10261/66327-
dc.description.abstractLocal translation of dendritic mRNAs is a key aspect of dendrite and spine morphogenesis and synaptic plasticity, two phenomena generally compromised in intellectual disability disorders. Mammalian target of rapamycin (mTOR) is a protein kinase involved in a plethora of functions including dendritogenesis, plasticity and the regulation of local translation. Hence, this kinase may well be implicated in intellectual disability. Hyperactivation of mTOR has been recently reported in mouse models of Fragile X and tuberous sclerosis, two important causes of intellectual disability. Moreover, local dendritic translation seems to be increased in Fragile X syndrome. Recent findings show that the mTOR pathway is also deregulated in murine models of Rett's syndrome and Down's syndrome. As in Fragile X, local dendritic translation seems to be abnormally active in Down's syndrome mice, while rapamycin, a Food and Drug Administration-approved mTOR inhibitor, restores normal rates of translation. Rapamycin administration in tuberous sclerosis mice rescues deficits in behavior and synaptic plasticity. Indeed, mTOR-dependent deregulation of local translation may be a common trait in different intellectual deficiencies, suggesting that mTOR inhibitors may have significant therapeutic potential for the treatment of diverse forms of cognitive impairment. © 2012 Elsevier Ltd.-
dc.description.sponsorshipThe present study was funded by the Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III, Spain; grant PI081401), Junta de Andalucía (grant P09-CTS-4610), and Fondation Jérôme Lejeune (France). We also thank Fundación Ramón Areces (Spain) for past financial support.-
dc.language.isoeng-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.titleDeregulated mTOR-mediated translation in intellectual disability-
dc.typeartículo-
dc.identifier.doi10.1016/j.pneurobio.2012.01.005-
dc.date.updated2013-02-07T14:22:52Z-
dc.description.versionPeer Reviewed-
dc.type.coarhttp://purl.org/coar/resource_type/c_6501es_ES
item.openairetypeartículo-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.languageiso639-1en-
Aparece en las colecciones: (IN) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Show simple item record

CORE Recommender

SCOPUSTM   
Citations

82
checked on 02-abr-2024

WEB OF SCIENCETM
Citations

71
checked on 27-feb-2024

Page view(s)

334
checked on 18-abr-2024

Download(s)

116
checked on 18-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.